ATE504595T1 - Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz - Google Patents

Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz

Info

Publication number
ATE504595T1
ATE504595T1 AT05784419T AT05784419T ATE504595T1 AT E504595 T1 ATE504595 T1 AT E504595T1 AT 05784419 T AT05784419 T AT 05784419T AT 05784419 T AT05784419 T AT 05784419T AT E504595 T1 ATE504595 T1 AT E504595T1
Authority
AT
Austria
Prior art keywords
diabetes
obesity
treatment
hyperlipidemia
hyperglycemia
Prior art date
Application number
AT05784419T
Other languages
English (en)
Inventor
Yu Huang
Xu Chen
Original Assignee
Generon Shanghai Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp filed Critical Generon Shanghai Corp
Application granted granted Critical
Publication of ATE504595T1 publication Critical patent/ATE504595T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05784419T 2005-01-04 2005-08-08 Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz ATE504595T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2005100231030A CN100515491C (zh) 2005-01-04 2005-01-04 白介素-22的医药用途
PCT/US2005/028186 WO2006073508A1 (en) 2005-01-04 2005-08-08 Use of il-22 for the treatment of conditions of metabolic disorders

Publications (1)

Publication Number Publication Date
ATE504595T1 true ATE504595T1 (de) 2011-04-15

Family

ID=35066920

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05784419T ATE504595T1 (de) 2005-01-04 2005-08-08 Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz

Country Status (9)

Country Link
US (4) US20100015086A1 (de)
EP (1) EP1841781B1 (de)
JP (1) JP5221959B2 (de)
CN (1) CN100515491C (de)
AT (1) ATE504595T1 (de)
AU (1) AU2005323392B2 (de)
CA (1) CA2592943C (de)
DE (1) DE602005027400D1 (de)
WO (1) WO2006073508A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103463096B (zh) * 2006-01-27 2016-03-16 耶鲁大学 胃酸分泌的快速作用抑制剂
CN101361968B (zh) * 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2010081112A1 (en) * 2009-01-12 2010-07-15 Yu Liang Huang Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
EP2737905B1 (de) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Verwendung eines g-csf-dimer bei der herstellung eines medikaments zur behandlung von neurodegenerativen erkrankungen
CN103182072B (zh) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 白介素‑22在治疗和预防神经损伤疾病或神经退行性疾病中的用途
WO2013177432A1 (en) * 2012-05-23 2013-11-28 The University Of Chicago Methods of treating obesity
JP6456356B2 (ja) 2013-03-15 2019-01-23 ジェネンテック， インコーポレイテッド ＩＬ−２２ポリペプチド及びＩＬ−２２Ｆｃ融合タンパク質並びに使用方法
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
CN104623639A (zh) * 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
ES2936067T3 (es) * 2014-05-27 2023-03-14 Univ Queensland IL-22 para uso en el tratamiento de trastornos metabólicos
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
MX2020013243A (es) 2018-06-05 2021-05-12 Bioatla Inc Anticuerpos anti-il-22, fragmentos de anticuerpo, sus inmunoconjugados y usos de los mismos.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
CA2145863A1 (en) * 1992-10-01 1994-04-28 Martha W. Bond Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6551799B2 (en) * 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6982320B2 (en) * 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
US20050271619A1 (en) * 1998-10-26 2005-12-08 Laure Dumoutier Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
US7081528B2 (en) * 1998-10-26 2006-07-25 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding T cell derived inducible factors
BR9914777A (pt) * 1998-10-26 2001-07-03 Ludwig Inst Cancer Res Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20030023033A1 (en) * 2001-07-26 2003-01-30 Laure Dumoutier Novel class II cytokine receptors and uses thereof
US20030235561A1 (en) * 2002-06-25 2003-12-25 Cell Based Delivery Inc. Vascularized organized tissues and uses thereof
US20040236075A1 (en) * 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
JP2007525437A (ja) * 2003-03-24 2007-09-06 ザイモジェネティクス， インコーポレイテッド 抗ｉｌ−２０抗体および結合パートナーならびに炎症において用いる方法

Also Published As

Publication number Publication date
US7666402B2 (en) 2010-02-23
EP1841781A4 (de) 2008-04-16
US7718604B2 (en) 2010-05-18
EP1841781B1 (de) 2011-04-06
DE602005027400D1 (de) 2011-05-19
CN100515491C (zh) 2009-07-22
US20100015086A1 (en) 2010-01-21
JP5221959B2 (ja) 2013-06-26
US20080069798A1 (en) 2008-03-20
WO2006073508A1 (en) 2006-07-13
US20080138314A1 (en) 2008-06-12
AU2005323392B2 (en) 2011-08-18
JP2008526740A (ja) 2008-07-24
AU2005323392A1 (en) 2006-07-13
EP1841781A1 (de) 2007-10-10
US20080069799A1 (en) 2008-03-20
US7696158B2 (en) 2010-04-13
CN1679918A (zh) 2005-10-12
CA2592943C (en) 2015-11-24
CA2592943A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
WO2010049678A3 (en) Treatment of energy utilization diseases
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
NO20084380L (no) Neuromedin U-reseptoragonister og anvendelser derav
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
AU2007221366A8 (en) Oxyntomodulin derivatives
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
DK1687049T3 (da) Sprøjter, sprøjtegrænseflader og sprøjtestempler til anvendelse med medicinske injektorer
ATE518859T1 (de) Neue fluorenderivate, zusammensetzung mit diesen derivaten und verwendung
NO20082531L (no) Neuropilinantagonister
EP1799263A4 (de) Reduzierung von er-stress bei der behandlung von adipositas und diabetes
DK1773361T4 (da) Sammensætning baseret på probiotiske bakterier og anvendelse deraf til forebyggelse og/eller behandling af respiratoriske sygdomme
DK3524261T3 (da) Exendin til anvendelse til behandling af diabetes og reduktion af kropsvægt
CL2008001126A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
IL200660A (en) Methods for producing 2,1-propanediol and e. coli is adapted to use these methods
CL2007001886A1 (es) Compuestos derivados de ureas de piperidina o pirrolidina; procedimiento de preparación; composición farmacéutica; y su uso como moduladores de la actividad de la 11ß-hidroxiesteroide deshidrogenasa tipo 1 (11ßhsd1) para tratar la obesidad, diabetes, resistenacia a la insulina, síndrome de cushing e hipertensión, entre otros.
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
DE602006000349D1 (de) Medizinisches Instrument mit medizinischer Behandlungselektrode
EP1900813A4 (de) Nesfatin, eine neue physiologische substanz, substanz in verbindung damit sowie verwendung der substanzen
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties